FDA Approves Neratinib for HER2-Positive Breast Cancer

The FDA has approved neratinib (Nerlynx) for use as extended adjuvant treatment in adult patients with early-stage HER2-positive breast cancer. (Source: CancerNetwork)

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2vkdifz
via IFTTT